AUTHORS
Emanuele Angelucci, MD, Mathilde Fekom, PhD2, Aleksandra Gavrilina, PhD3, Rawad Rihani, MD4, Yener Koc, MD5, Ashrafsadat Mousavi, MD6, Michael Potter, MD7, Giovanni Caocci, MD8, Franco Locatelli, MD PhD9, Mohsen Alzahrani Sr, MD10, Zubeyde Nur Ozkurt, MD11, Selim Corbacioglu, MD12, Valeria Pinto13, Josu de la Fuente, PhD FRCP FRCPCH FRCPath14
AFFILIATIONS
1 AOM-IRCCS Ospedale Policlinico San Martino., Genova, Liguria, Italy
2 European Society for Blood and Marrow Transplantation, Paris, France
3 European Society for Blood and Marrow Transplantation, Paris, France
4 King Hussein Cancer Centre, Amman, Jordan
5 Medicana International Hospital Istambul, Istanbul, Turkey, Medicana International Hospital Istanbul, Istambul, Turkey
6 Shariati Hospital, Tehran, Iran
7 The London Clinic Harley Street, London, United Kingdom
8 A. O Brotzu, Cagliari, Italy
9 IRCCS, Ospedale Pediatrico Bambino Gesù Rome, Catholic University of the Sacred Heart, Rome, Italy
10 King Abdul - Aziz Medical City, Riyadh, Saudi Arabia
11 Gazi University Faculty of Medicine, Ankara, Turkey
12 University of Regensburg, Regensburg, Germany
13 AOM-IRCCS Ospedale Policlinico San Martino., Genova, Liguria, Italy
14 Imperial College Healthcare NHS Trust, London, United Kingdom
ABSTRACT
Introduction
Over the past 30 years, allogeneic hematopoietic cell transplantation (HCT) has not been the focus of specific studies in adult patients with transfusion-dependent thalassemia (TDT). The only dedicated publications date back to the deferoxamine-only era (Blood 1992; 80:1603 and Blood 1999; 93:1164) and reported disappointing results, discouraging the use of HCT in adult patients in subsequent years. In more recent years limited data were published within the context of larger transplantation studies (Bone Marrow Transplant 2016; 51:536 and Blood Adv 2019; 3:2562).
Since these preliminary reports were published, improvements have been made to transplant techniques, HLA typing, and, most importantly, transfusion and iron chelation strategies. In response to this deficit, the EBMT-Hemoglobinopathies working party analyzed adult TDT patients in the EBMT registry to provide updated outcome data.
Methods
Data cut was July 1st, 2026, for 224 consecutive patients (124 males and 100 females) transplanted between 2010 and 2024 at 56 EBMT centers, with more than half (N=140) at 10 centers. Median age was 22.5 years (interquartile range [IQR] 20.1-26.7, range 18-44.8). Median duration of transfusion dependency before HCT was 22 years (IQR 19.6-26). Median serum ferritin was 1695 microg/dl (IQR 1029-2191). Donor was an HLA-identical sibling in 67%, a mismatched family donor in 9%, a matched unrelated donor in 12%, and a mismatched unrelated donor in 11%. Seventy-two percent of patients received a busulfan-based conditioning, and 28% received a treosulfan-based conditioning. As GvHD prophylaxis, 40 patients received post-transplant cyclophosphamide, five received in vivo T-cell depletion, and the remaining received various cyclosporine- or MMF-based regimens. Median follow-up was three years (range 2.6-4). The event was defined as recurrent transfusion dependency. Survival data are expressed as median (95% confidence interval [CI]).
Results
In the entire study population, 3-year overall survival (OS) and event-free survival (EFS) were 84.5% (95% CI: 78.7–88.8) and 75.4% (95% CI: 68.1–81.2), respectively. The 3-year incidence of grade III–IV acute GvHD and chronic GvHD was 8.6% (95% CI: 5.1–13.1) and 3.5% (95% CI: 1.3–7.5), respectively.
Regarding the donor, OS and EFS were 86.9% (95% CI 80.2–91.4) and 81.1% (95% CI 73.1–86.9) for patients who received a transplant from an HLA-matched related donor; 83.3% (95% CI 56.4–94.4) and 69.9% (95% CI 42–86.3) for an HLA-mismatched related donor; 91.3% (95% CI 69.5–97.8) and 84.4% (95% CI 58.9–94.7) for an HLA-matched unrelated donor; and 79.4% (95% CI 48.8–92.9) and 69.9% (95% CI 42–86.3) for an HLA-mismatched unrelated donor.
For the analysis, patients were divided into three groups based on the transplant time period (2010–2013: n=60; 2014–2017: n=84; 2018–2024: n=80). Two-year OS and EFS rates were 79.2% (95% CI: 64.9–88.2) and 76.2% (95% CI: 60.1–86.5) in the first group, 79.9% (95% CI: 69.1–87.2) and 72.5% (95% CI: 60.2–81.6) in the second, and 93.1% (95% CI: 84.2–97.1) and 80.3% (95% CI: 67.8–88.4) in the most recent period.
In centers with greater experience (more than 4 adult patients transplanted, compared with those with lower activity), 3-year overall survival (OS) and event-free survival (EFS) were 87.5% (95% CI: 81.3–91.8) and 78.7% (95% CI: 70.7–84.8), respectively, compared with 81.1% (95% CI: 60.4–91.7) and 63.7% (37.7–81.1).
In 63 patients (median age 23.4 years (IQR 20.3- 28)) who received an HLA-identical donor (related and unrelated) in the most recent period, 4-year OS and EFS were 94.8% (95% CI 84.8- 98.3) and 77.9% (95% CI 62.2- 87.7), respectively.
Conclusions
These results, derived from real-world clinical practice and unselected populations, indicate that the outcomes of HCT in adults with TDT have improved in recent years, and can serve as a benchmark for recently introduced gene therapy.
DISCLOSURES
Emanuele Angelucci, MD: BMS - Honoraria; Vertex - Honoraria; Menarini-Stemline - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)